←
Alex Plesa162 posts
Alex Plesa avatar

Alex Plesa

@amplesa

Scientist at @harvardmed and @WyssInstitute in @geochurch's lab | Working on solving aging

◷ Joined October 2019▧ 12 Photos and videos
Alex Plesa avatar
Alex Plesa@amplesa·Oct 16

Our paper is out in @NatureAging. We looked for factors that make old cells' gene expression young without erasing their identity. SRSF1 came out as a promising rejuvenation target that reduced aging hallmarks in human cells and extended median lifespan of aged mice by 14%. 1/4

Post attachment
Mike Riggs avatar
⟳ Alex Plesa retweeted
Mike Riggs@MikeRiggs·Nov 13

This is why @amplesa argues we need more/better instruments, not more of the same data we can already collect, in order to get more from AIxBio: amplesa.substack.com/p/ai-fo…

This is an important paper to read for tamping down some of the "AI will solve biology" enthusiasm. The researchers pretrained 400 models on a corpus of 22.2 million cells and performed 6,400 evaluations. They found that current single-cell foundation-model approaches frequently plateaued at substantially smaller training sizes and did not exhibit clear data scaling laws analogous to language models. Importantly, this suggests that simply collecting more of the same kind of single-cell data is not necessarily the solution. Better coverage of biological states, conditions, perturbations and relevant endpoints may matter more. One of the key things to realize about biology is how emergent and heterogeneous it is, which means that simply gathering more data at one level is insufficient for developing foundation models, designing better drugs etc. We need *relevant* data at scale for many different levels and interactions, including single gene, multi-gene, gene-protein, protein-protein, cell-cell etc. A lot of this data - for instance spatial cell-cell data -is not easy to acquire at large scale, and we have just started to do it. And even when we have that, the reasoning models will have to figure out which one of these data types is most suitable for a particular problem. I see a lot of progress using AI for data analysis and gathering in biology in the future, but it's critical to recognize how the data problem for AI in biology is fundamentally different from the data problem in areas like image and text analysis (which is hard to begin with). nature.com/articles/s41592-0…

Alex Plesa avatar
Alex Plesa@amplesa·Nov 2

Most of the cells in your body are younger than you are. Yet, you still age. Why? I explore this in my new post. Link in the reply.

Post attachment
Patrick Mineault avatar
⟳ Alex Plesa retweeted
Patrick Mineault@patrickmineault·Oct 30

We've been trying to put new neurons in the CNS for ~40 years. One cell therapy for Parkinson's disease is conditionally approved in Japan; a couple more are down the pipe. What's the upper bound on this modality? What's taking so long? And could it be accelerated by AI?

Post attachment
Olya Irzak avatar
⟳ Alex Plesa retweeted
Olya Irzak@Olya_Irzak·Oct 27

We've shown that the GHG footprint of behind-the-meter gas powered datacenters is twice what was previously thought - due to methane. Low cost solution exist: meritcert.org/ Thanks @shaylekann for having me on the podcast and @hausfath for the writeup!

Great discussion with Olya Irzak on just how high the methane leakage may be from off-grid data centers powered by low-efficiency reciprocating gas engines. Another reason to ensure that if data centers are built, they are on the grid! latitudemedia.com/news/catal…

Alex Araki avatar
⟳ Alex Plesa retweeted
Alex Araki@alexsaraki·Oct 23

Announcing Ikigai Grants: Microgrants give early-stage, bootstrapped talent capital. But that’s not enough. I’ve watched too many grantees become perpetual microgrant chasers, wasting time applying to one $5k grant after another. Worse, most programs encourage this by funding the blanket “smart people doing cool things,” with no real conviction behind it. I wouldn’t be here without patronage from @tylercowen & @jposhaughnessy. But looking back, the mentors & community were worth much more than the money. So I built the program I always wished existed: - $50k total, avg. $5k check - Matched with mentors & community across @RenPhilanthropy , Fulcrum Science, and my personal network of founders, fund leads, investors & scientists. Cohort 1 backs emerging talent in areas I believe are deeply underfunded and undervalued. Every application is reviewed by me. Ikigai Grants is a program of @RenPhilanthropy, with support from Fulcrum Science. Advised by many wonderful friends & colleagues including: @AshleyNAbel @RaianyRomanni @NeuroStats Bonnie EJ Maven @idatin @ashleyz413 @JackScannell13 Apply by Nov 9th, 9a PST: alexaraki.xyz/ikigai

Post attachment
Helen Wang avatar
⟳ Alex Plesa retweeted
Helen Wang@wanghelenh·Oct 16

So proud to have been part of this work on cellular rejuvenation through identity-preserving reprogramming, out now in @NatureAging! Grateful to my mentors @geochurch @amplesa and all of our co-authors. nature.com/articles/s43587-0…

Our paper is out in @NatureAging. We looked for factors that make old cells' gene expression young without erasing their identity. SRSF1 came out as a promising rejuvenation target that reduced aging hallmarks in human cells and extended median lifespan of aged mice by 14%. 1/4

Post attachment
Alex Plesa avatar
Alex Plesa@amplesa·Oct 16

Thanks to @geochurch, Sascha Jung, and all our co-authors. You can find the paper here: nature.com/articles/s43587-0… Free to read: rdcu.be/ypTLcckieF8a And more on the initial screen here: x.com/amplesa/status/1737852… 4/4

Can we reverse aging? 7 yrs ago, Ocampo et al. showed that partial reprogramming can ameliorate aging hallmarks. But, OSKM induction has safety limitations & no new factors have emerged since. Here, biorxiv.org/content/10.1101/… we used 🧬 screens to find new rejuvenation factors🧵1/8

Alex Plesa avatar
Alex Plesa@amplesa·Oct 16

Two new results since the preprint: SRSF1 reduced DNAm age of old fibroblasts, and there was no activation of pluripotency programs. Still, this is in human cells and mice; we need to figure out delivery and dosing, and ideally have another lab replicate the lifespan. 3/4

Alex Plesa avatar
Alex Plesa@amplesa·Oct 16

We used a single dose of liver-directed AAV delivering SRSF1, cycling expression on and off every other week in ~20-month-old mice. Frailty accumulated ~44% more slowly, and median lifespan was extended. 2/4

Post attachment
Patrick Mineault avatar
⟳ Alex Plesa retweeted
Patrick Mineault@patrickmineault·Sep 30

There's a new imaging modality in town: functional ultrasound imaging. I went down a deep rabbit hole to understand how it works computationally. Read all about how it works physically and how *you* can improve it..

Post attachment
C5R CORP avatar
⟳ Alex Plesa retweeted
C5R CORP@c5rcorp·Sep 24

In 12 weeks, we built a research facility that is run entirely by AI. AI designs, executes, and observes experiments end-to-end across biology, chemistry, and materials science. We’re introducing SciUniverse: a benchmark that measures AI’s ability to do real-world scientific research.

1:46
Zane Koch avatar
⟳ Alex Plesa retweeted
Zane Koch@zanehkoch·Sep 18

Science – debatably the #1 journal in the world – published a paper on a "virtual biotech" AI system this week but the authors never even test if it works well! all the evidence for its performance is 3 anecdotes the paper has no benchmark scores, no baselines, no replicates

Post attachment
Alan Tomusiak avatar
⟳ Alex Plesa retweeted
Alan Tomusiak@alantomusiak·Sep 9

One of the most comprehensive studies of human mutations across tissues and age was released last week. 53 cell types, 172 people, ages 0-93. Many takeaways, but the big highlight is that mutation rates vary a lot - and not in the ways you'd expect. A thread:

Post attachmentPost attachment